Navigation Links
Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in Atlanta (December 8-11, 2012). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL).

Studies presented at this year's ASH meeting will report the complete Phase 2 data set from a study demonstrating that Iomab-B (monoclonal antibody BC8 labeled with Iodine 131) provides a significant survival benefit for high risk AML patients under age 50.  At the time of the abstract writing, 36% of the patients were surviving progression free for a median of 87 months.  Other data to be presented at the meeting include Phase I dose escalating trial in enabling successful engraftment and complete remissions in transplanting patients who do not have fully matched donors.   All the patients in the trial were successfully transplanted and had a complete remission with survival benefit.

The following abstracts will be presented during the 54th Annual ASH Meeting and Exposition:

Abstract #1924:  A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Saturday, December 8, 2012, 5:30 PM - 7:30 PM (Georgia World Congress Center, Hall B1-B2)

Abstract #4164:  Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Monday, December 10, 2012, 6:00 PM - 8:00 PM (Georgia World Congress Center, Hall B1-B2)

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site or contact:

Dennis S. Dobson Jr. of Dennis S. Dobson Inc., 203-258-0159

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201

Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Salveo Specialty Pharmacy, Inc. Completes Additional Equity and Debt Financings and Acquisition of Mission Road Pharmacy
2. Women with Dense Breasts Welcome Additional Screening
3. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
4. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
5. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
6. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
7. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
8. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
9. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. GeNO LLC Receives Two Additional Patents For Inhaled Nitric Oxide Drug Delivery
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... people across the country to celebrate their sobriety and show through pictures what ... “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
Breaking Medicine News(10 mins):